Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced - Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 29, 2023

Primary Completion Date

May 20, 2025

Study Completion Date

May 20, 2025

Conditions
IC - Interstitial Cystitis
Interventions
DRUG

Ferumoxytol

After fully emptying the bladder with a catheter,1.5mg of Ferumoxytol combined with Gadobutrol 302 mg will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to an MRI scan of the bladder. After the MRI is completed, the Ferumoxytol will be drained through the catheter and the catheter will be removed.

DRUG

Gadobutrol

After fully emptying the bladder with a catheter, 302 mg of Gadobutrol (combined with Ferumoxytol) will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to a MRI scan of the bladder. After the MRI is completed, the Gadobutrol will be drained through the catheter and the catheter will be removed.

Trial Locations (1)

15213

UPMC Magee Women's Hospital, Pittsburgh

Sponsors
All Listed Sponsors
collaborator

Lipella Pharmaceuticals, Inc.

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

lead

Christopher J Chermansky, MD

OTHER

NCT05811377 - Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced - Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay | Biotech Hunter | Biotech Hunter